1. Home
  2. UNCY vs BHST Comparison

UNCY vs BHST Comparison

Compare UNCY & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UNCY
  • BHST
  • Stock Information
  • Founded
  • UNCY 2016
  • BHST 2007
  • Country
  • UNCY United States
  • BHST Canada
  • Employees
  • UNCY N/A
  • BHST N/A
  • Industry
  • UNCY Biotechnology: Pharmaceutical Preparations
  • BHST
  • Sector
  • UNCY Health Care
  • BHST
  • Exchange
  • UNCY Nasdaq
  • BHST Nasdaq
  • Market Cap
  • UNCY 91.0M
  • BHST 106.0M
  • IPO Year
  • UNCY 2021
  • BHST N/A
  • Fundamental
  • Price
  • UNCY $6.34
  • BHST $7.06
  • Analyst Decision
  • UNCY Strong Buy
  • BHST Strong Buy
  • Analyst Count
  • UNCY 4
  • BHST 2
  • Target Price
  • UNCY $6.38
  • BHST $13.00
  • AVG Volume (30 Days)
  • UNCY 867.0K
  • BHST 11.9K
  • Earning Date
  • UNCY 08-13-2025
  • BHST 08-15-2025
  • Dividend Yield
  • UNCY N/A
  • BHST N/A
  • EPS Growth
  • UNCY N/A
  • BHST N/A
  • EPS
  • UNCY N/A
  • BHST N/A
  • Revenue
  • UNCY N/A
  • BHST $27,704,000.00
  • Revenue This Year
  • UNCY N/A
  • BHST $116.40
  • Revenue Next Year
  • UNCY $1,458.53
  • BHST $55.91
  • P/E Ratio
  • UNCY N/A
  • BHST N/A
  • Revenue Growth
  • UNCY N/A
  • BHST 74.76
  • 52 Week Low
  • UNCY $2.02
  • BHST $4.66
  • 52 Week High
  • UNCY $11.00
  • BHST $7.86
  • Technical
  • Relative Strength Index (RSI)
  • UNCY 48.29
  • BHST N/A
  • Support Level
  • UNCY $4.70
  • BHST N/A
  • Resistance Level
  • UNCY $7.58
  • BHST N/A
  • Average True Range (ATR)
  • UNCY 1.20
  • BHST 0.00
  • MACD
  • UNCY -0.07
  • BHST 0.00
  • Stochastic Oscillator
  • UNCY 26.03
  • BHST 0.00

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

About BHST BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

Share on Social Networks: